Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Revenues Increase 25%

Published: Wednesday, January 29, 2014
Last Updated: Wednesday, January 29, 2014
Bookmark and Share
Company announces financial results for the fourth quarter and fiscal year 2013.

Fourth quarter 2013 results: 

  • Revenue of $387 million, a 25% increase compared to $309 million in the fourth quarter of 2012 
  • GAAP net income for the quarter of $81 million, or $0.56 per diluted share, compared to $72 million, or $0.53 per diluted share, for the fourth quarter of 2012 
  • Non-GAAP net income for the quarter of $65 million, or $0.45 per diluted share, compared to $57 million, or $0.42 per diluted share, for the fourth quarter of 2012 (see the table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures) 
  • Cash flow from operations of $127 million and free cash flow of $100 million for the quarter 

Gross margin in the fourth quarter of 2013 was 66.9% compared to 65.8% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation, amortization of acquired intangible assets, legal contingencies, and inventory revaluation adjustments, non-GAAP gross margin was 71.4% for the fourth quarter of 2013 compared to 68.5% in the prior year period. 

Research and development (R&D) expenses for the fourth quarter of 2013 were $76.7 million compared to $56.9 million in the fourth quarter of 2012. R&D expenses included $10.9 million and $8.0 million of non-cash stock compensation expense in the fourth quarters of 2013 and 2012, respectively. Excluding these charges and contingent compensation, R&D expenses as a percentage of revenue were 17.0% compared to 15.4% in the prior year period. 

Selling, general and administrative (SG&A) expenses for the fourth quarter of 2013 were $111.6 million compared to $79.7 million for the fourth quarter of 2012. SG&A expenses included $16.8 million and $14.1 million of non-cash stock compensation expense in the fourth quarters of 2013 and 2012, respectively. Excluding these charges, contingent compensation and amortization of acquired intangible assets, SG&A expenses as a percentage of revenue were 22.2% compared to 19.9% in the prior year period. 

Depreciation and amortization expenses were $27.2 million and capital expenditures were $27.3 million during the fourth quarter of 2013. The Company ended the fourth quarter of 2013 with $1.17 billion in cash, cash equivalents and short-term investments, compared to $1.35 billion as of December 30, 2012. 

Fiscal 2013 results: 

  • Revenue of $1.42 billion, a 24% increase over the $1.15 billion reported in fiscal 2012 
  • GAAP net income of $125 million, or $0.90 per diluted share, compared to $151 million, or $1.13 per diluted share in fiscal 2012 
  • Non-GAAP net income of $250 million, or $1.80 per diluted share, compared to $210 million, or $1.59 per diluted share, in fiscal 2012 (see table entitled "Itemized Reconciliation Between GAAP and Non-GAAP Net Income" for a reconciliation of these GAAP and non-GAAP financial measures) 

Gross margin for fiscal 2013 was 64.2% compared to 67.4% in fiscal 2012. Cost of product sales during 2013 included impairment charges of $25.2 million related to a decision to discontinue a non-core product line. Excluding the effect of these charges as well as non-cash charges associated with stock compensation, amortization of acquired intangible assets, legal contingencies, and inventory revaluation adjustments, non-GAAP gross margin was 70.1% for fiscal 2013 compared to 69.7% in fiscal 2012. 

R&D expenses for fiscal 2013 were $276.7 million compared to $231.0 million in fiscal 2012. R&D expenses included $37.4 million and $30.9 million of non-cash stock compensation expense in fiscal 2013 and 2012, respectively. R&D expenses for fiscal 2012 included an impairment charge of $21.4 million related to an in-process research and development asset. Excluding these charges and contingent compensation, R&D expenses as a percentage of revenue were 16.8% compared to 15.3% in the prior year. 

SG&A expenses for fiscal 2013 were $381.0 million compared to $286.0 million in fiscal 2012. SG&A expenses included $61.4 million and $55.4 million of non-cash stock compensation expense in fiscal 2013 and 2012, respectively. Excluding these charges, contingent compensation, and amortization of acquired intangible assets, SG&A expenses as a percentage of revenue were 20.8% compared to 19.5% in the prior year. 

"The fourth quarter capped off a spectacular year for Illumina with robust performance across all products and geographies," stated Jay Flatley, CEO. "We made significant progress on key R&D programs which allowed us to introduce new products in early 2014 that will once again redefine the trajectory of sequencing. We plan to leverage this momentum in 2014 to more broadly enable the adoption of genomics." 

Updates since last earnings release: 

Introduced HiSeq XTM Ten Sequencing System, enabling 'factory scale' sequencing and announced sales to Macrogen, the Broad Institute, the Garvan Institute of Medical Research, and the New York Genome Center 

Launched NextSeqTM 500 Sequencing System, a new platform that packs high-throughput performance into an affordable desktop sequencer 

Announced plans to simplify library preparation with NeoPrepTM, a push-button, library-preparation system 

Launched BaseSpace® OnSite, a simple informatics appliance that enables users to securely stream data to a local, private cloud 

Unveiled new enhancements to the HiSeq® family of instruments, which will enable certain HiSeq instruments to produce 1 terabase of sequencing data 

Announced that Illumina received premarket clearance from the U.S. Food and Drug Administration (FDA) for the MiSeqDxTM system, MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit 

Acquired NextBio, a leader in analyzing and aggregating complex genomic data 

Entered into multi-year licensing agreements with Quest Diagnostics and LabCorp to use Illumina's NGS technology for clinical laboratory testing 

Entered into an agreement with Amgen to develop an Oncology Companion Diagnostic Test on the FDA-Cleared MiSeqDx NGS Instrument 

Further strengthened Illumina's management team by appointing Francis deSouza to the role of President 

Additional updates not highlighted above can be found on our investor relations webpage: http://investor.illumina.com 

Financial outlook and guidance 
The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures. 

For fiscal 2014 the Company is projecting approximately 15% to 17% revenue growth and non-GAAP earnings per fully diluted share of $2.00 to $2.06. These projections assume full year non-GAAP gross margin of approximately 70.0%, a pro forma tax rate of approximately 29.5% and stock compensation expense of approximately $128 million. Full-year weighted average diluted shares outstanding, for the measurement of pro forma amounts, is expected to be approximately 148 million shares assuming a stock price of $114.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Illumina Announces Strategic Collaboration with Merck Serono
Collaboration to expand companion diagnostics for oncology.
Friday, March 13, 2015
Illumina and Merck Serono Collaborate
Strategic collaboration will expand companion diagnostics for oncology.
Tuesday, March 10, 2015
Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates
Obtains commitment from viking global investors to advance genomics startups.
Friday, February 27, 2015
Illumina Q4 Revenues Up 32%
Illumina has announced its financial results for the fourth quarter and fiscal year 2014.
Wednesday, January 28, 2015
£15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare
Initiative sees the Universities of Edinburgh and Glasgow partner with Illumina.
Monday, January 12, 2015
Illumina Announces AOCC to Receive Agricultural Greater Good Initiative Grant
Project designed to improve food security in Africa.
Friday, January 09, 2015
Illumina and Sequenom Enter Settlement
Illumina and Sequenom pool noninvasive prenatal testing intellectual property and end outstanding patent disputes.
Wednesday, December 03, 2014
USAID, Broad Institute and Illumina Form a Public-Private Partnership
Partnership aims to combat the Ebola epidemic in West Africa.
Wednesday, November 19, 2014
Actionable Genome Consortium Forms
Consortium will recommend standards for applying Next-Generation Sequencing to cancer tumors.
Monday, September 08, 2014
Scientific News
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
Web App Helps Researchers Explore Cancer Genetics
Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
New Research Advances Genetic Studies in Wildlife Conservation
‘Next-gen’ DNA sequencing of non-invasively collected hair expands field of conservation genetics.
Gene Testing Now Allows Precision Medicine for Thoracic Aneurysms
Researchers at the Aortic Institute at Yale have tested the genomes of more than 100 patients with thoracic aortic aneurysms, a potentially lethal condition, and provided genetically personalized care.
OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Sperm RNA Test May Improve Evaluation of Male Infertility
To help resolve uncertainty—and guide prospective parents to the right fertility treatments—scientists propose the use of a new kind of fertility test. It involves examining sperm RNA by means of next-generation sequencing.
How the Mammoth Got its Wool
Evolutionary change in a gene reconstructed in the lab from the woolly mammoth was part of a suite of adaptations that allowed the mammoth to survive in harsh arctic environments, according to new research.
NuGEN Scientists Screen 400+ Genes for Fusion Events in Single Assay
Breakthrough proves efficacy of new sample preparation method that could accelerate cancer research and development of treatments and diagnostic tests.
More Accurate and Comprehensive Whole Genome Assembly
Scientists from the Icahn School of Medicine at Mount Sinai have developed a new approach to build nearly complete genomes by combining high-throughput DNA sequencing with genome mapping.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!